Eliassen Group Honored by Inc. Magazine as One of America's Fastest-Growing Private Companies

Eliassen Group Honored by Inc. Magazine as One of America's Fastest-Growing Private Companies
Largest Tech Staffing Firm in Boston Experiences Rapid Growth Despite Economic Downturn
 

WAKEFIELD, Mass. -- Eliassen Group, a leading technology staffing and clinical data management consulting firm, today announced that the company has been named to Inc. magazine's fourth annual Inc. 5000, an exclusive ranking of the nation's fastest-growing private companies based on percentage revenue growth from 2006 to 2009. With its fourth consecutive win, Eliassen Group was selected not only for its average revenue growth of 27.86 percent and average employee growth of 11 percent over the last three years, but also for its development and expansion in and around the Northeast, totaling six offices in the region and growing.

"It's an honor for Eliassen Group to be recognized for all the hard work our employees have put into growing the company not just over the past three years, but since the company's inception from which we have more than 20 years of experience under our belt," said Dave MacKeen, CEO, Eliassen Group. "This award is particularly important to us since it proves Eliassen Group's resiliency when faced with the challenging economic conditions, through which we have not only maintained our market presence, but significantly expanded the footprint in both our technology staffing and clinical research divisions."

Since 1989, Eliassen Group has provided IT and software professionals on a contract, contract-to-hire and direct-hire basis across a multitude of industries, including healthcare, biopharmaceutical, financial services, government, education, manufacturing and software development, making it the largest staffing firm devoted to IT in the Boston area. The company continues to build upon its already deep-seeded knowledge base through the additions of innovative technology practice areas including Agile Methodology, Validation and Learning services as well as clinical data management via its eClinical Solutions division, founded in 2006.

"The leaders of the companies on this year's Inc. 5000 have figured out how to grow their businesses during the longest recession since the Great Depression," said Inc. president Bob LaPointe. "The 2010 Inc. 5000 showcases a particularly hardy group of entrepreneurs."

Each year, Inc. celebrates the achievements of today's fastest-growing private companies with the Inc. 500|5000 Conference & Awards Ceremony, which brings together members of the Inc. community, both a new class of Inc. 500|5000 honorees and the list's alumni, from September 30-October 2, 2010, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

Founded in 1979 and acquired in 2005 by Mansueto Ventures LLC, Inc. (www.inc.com) is the only major business magazine dedicated exclusively to owners and managers of growing private companies that delivers real solutions for today's innovative company builders. With a total paid circulation of 712,647, Inc. provides hands-on tools and market-tested strategies for managing people, finances, sales, marketing, and technology. Visit us online at www.inc.com.

About Eliassen Group

Eliassen Group, headquartered in Wakefield, MA, is composed of two divisions: Technology Staffing and eClinical Solutions. The Technology Staffing Division provides services to clients nationwide in industries including healthcare/pharmaceutical, financial services, government, education, manufacturing and software development (www.eliassen.com). eClinical Solutions provides data management services, EDC services, statistical programming, training solutions, reporting solutions, strategic consulting, user acceptance testing (UAT)/validation Services, as well as clinical data repository development and management for pharmaceutical, biotechnology and medical device companies (www.eclinicalsol.com). For more information, please contact us at 800-354-2773.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.